JP2010505956A - Apo−bレベル低下のためのオメガ−3脂肪酸および脂質異常症剤 - Google Patents
Apo−bレベル低下のためのオメガ−3脂肪酸および脂質異常症剤 Download PDFInfo
- Publication number
- JP2010505956A JP2010505956A JP2009532391A JP2009532391A JP2010505956A JP 2010505956 A JP2010505956 A JP 2010505956A JP 2009532391 A JP2009532391 A JP 2009532391A JP 2009532391 A JP2009532391 A JP 2009532391A JP 2010505956 A JP2010505956 A JP 2010505956A
- Authority
- JP
- Japan
- Prior art keywords
- omega
- fatty acid
- levels
- subject group
- apo
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
- A61K31/232—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having three or more double bonds, e.g. etretinate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US85028006P | 2006-10-10 | 2006-10-10 | |
PCT/US2007/021631 WO2008045465A1 (fr) | 2006-10-10 | 2007-10-10 | Acides gras oméga-3 et agent dyslipidémique pour la réduction des niveaux d'apo-b |
Publications (1)
Publication Number | Publication Date |
---|---|
JP2010505956A true JP2010505956A (ja) | 2010-02-25 |
Family
ID=39283166
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2009532391A Pending JP2010505956A (ja) | 2006-10-10 | 2007-10-10 | Apo−bレベル低下のためのオメガ−3脂肪酸および脂質異常症剤 |
Country Status (10)
Country | Link |
---|---|
EP (1) | EP2089014A4 (fr) |
JP (1) | JP2010505956A (fr) |
KR (1) | KR20090080070A (fr) |
CN (2) | CN101553221A (fr) |
AU (1) | AU2007307007A1 (fr) |
BR (1) | BRPI0719182A2 (fr) |
CA (1) | CA2672919A1 (fr) |
EA (2) | EA018734B1 (fr) |
MX (1) | MX2009003921A (fr) |
WO (1) | WO2008045465A1 (fr) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2014034871A1 (fr) * | 2012-08-30 | 2014-03-06 | 株式会社 三和化学研究所 | Médicament pour la prévention ou le traitement de la dyslipidémie |
Families Citing this family (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8784886B2 (en) | 2006-03-09 | 2014-07-22 | GlaxoSmithKline, LLC | Coating capsules with active pharmaceutical ingredients |
JP2010506920A (ja) * | 2006-10-18 | 2010-03-04 | リライアント・ファーマシューティカルズ・インコーポレイテッド | Lp−pla2濃度を減少させるためのオメガ−3脂肪酸 |
EP4137128A1 (fr) | 2008-09-02 | 2023-02-22 | Amarin Pharmaceuticals Ireland Limited | Composition pharmaceutique contenant de l'acide eicosapentaénoïque et leurs procédés d'utilisation |
NZ594395A (en) | 2009-02-10 | 2014-01-31 | Amarin Pharmaceuticals Ie Ltd | Use of eicosapentaenoic acid ethyl ester for treating hypertriglyceridemia |
NZ720946A (en) | 2009-04-29 | 2017-09-29 | Amarin Pharmaceuticals Ie Ltd | Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same |
MX2011011538A (es) | 2009-04-29 | 2012-06-13 | Amarin Pharma Inc | Composicion farmaceutica estable y metodos de uso de la misma. |
SI3318255T1 (sl) | 2009-06-15 | 2021-07-30 | Amarin Pharmaceuticals Ireland Limited | Kompozicije in metode za zdravljenje kapi pri subjektu, ki prejema sočasno zdravljenje s statinom |
CA2775339C (fr) | 2009-09-23 | 2017-03-28 | Amarin Corporation Plc | Composition pharmaceutique comportant de l'acide gras omega-3 et derive hydroxy d'une statine et procedes d'utilisation de ceux-ci |
US11712429B2 (en) | 2010-11-29 | 2023-08-01 | Amarin Pharmaceuticals Ireland Limited | Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity |
AU2011336856A1 (en) | 2010-11-29 | 2013-07-04 | Amarin Pharmaceuticals Ireland Limited | Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity |
US11291643B2 (en) | 2011-11-07 | 2022-04-05 | Amarin Pharmaceuticals Ireland Limited | Methods of treating hypertriglyceridemia |
US20130131170A1 (en) | 2011-11-07 | 2013-05-23 | Amarin Pharmaceuticals Ireland Limited | Methods of treating hypertriglyceridemia |
WO2013103958A1 (fr) | 2012-01-06 | 2013-07-11 | Amarin Pharmaceuticals Ireland Limited | Compositions et procédés pour abaisser les taux de crp à haute sensibilité (hs-crp) chez un sujet |
MX2020013922A (es) | 2012-06-29 | 2022-08-15 | Amarin Pharmaceuticals Ie Ltd | Metodos para reducir riesgo de evento cardiovascular en sujeto con terapia con estatina. |
CN102824636A (zh) * | 2012-08-15 | 2012-12-19 | 四川大学 | 一种含他汀类药物和多不饱和脂肪酸的药物组合物及其用途 |
WO2014074552A2 (fr) | 2012-11-06 | 2014-05-15 | Amarin Pharmaceuticals Ireland Limited | Compositions et procédés pour diminuer les triglycérides sans augmenter les taux de ldl-c chez un sujet traité en même temps par la statine |
US9814733B2 (en) | 2012-12-31 | 2017-11-14 | A,arin Pharmaceuticals Ireland Limited | Compositions comprising EPA and obeticholic acid and methods of use thereof |
US20140187633A1 (en) | 2012-12-31 | 2014-07-03 | Amarin Pharmaceuticals Ireland Limited | Methods of treating or preventing nonalcoholic steatohepatitis and/or primary biliary cirrhosis |
US9452151B2 (en) | 2013-02-06 | 2016-09-27 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing apolipoprotein C-III |
US9624492B2 (en) | 2013-02-13 | 2017-04-18 | Amarin Pharmaceuticals Ireland Limited | Compositions comprising eicosapentaenoic acid and mipomersen and methods of use thereof |
US9662307B2 (en) | 2013-02-19 | 2017-05-30 | The Regents Of The University Of Colorado | Compositions comprising eicosapentaenoic acid and a hydroxyl compound and methods of use thereof |
US9283201B2 (en) | 2013-03-14 | 2016-03-15 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for treating or preventing obesity in a subject in need thereof |
US20140271841A1 (en) | 2013-03-15 | 2014-09-18 | Amarin Pharmaceuticals Ireland Limited | Pharmaceutical composition comprising eicosapentaenoic acid and derivatives thereof and a statin |
US10966968B2 (en) | 2013-06-06 | 2021-04-06 | Amarin Pharmaceuticals Ireland Limited | Co-administration of rosiglitazone and eicosapentaenoic acid or a derivative thereof |
US20150065572A1 (en) | 2013-09-04 | 2015-03-05 | Amarin Pharmaceuticals Ireland Limited | Methods of treating or preventing prostate cancer |
US9585859B2 (en) | 2013-10-10 | 2017-03-07 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy |
DK3102212T3 (en) * | 2014-02-05 | 2019-02-11 | Dezima Pharma B V | Cholesteryl ester transfer protein (CETP) inhibitors and pharmaceutical compositions comprising the inhibitor for use in the treatment or prevention of cardiovascular disease |
US10561631B2 (en) | 2014-06-11 | 2020-02-18 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing RLP-C |
US10172818B2 (en) | 2014-06-16 | 2019-01-08 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids |
US10406130B2 (en) | 2016-03-15 | 2019-09-10 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids |
WO2018213663A1 (fr) | 2017-05-19 | 2018-11-22 | Amarin Pharmaceuticals Ireland Limited | Compositions et méthodes pour dimunuer les triglycérides chez un sujet ayant une fonction rénale réduite |
US11058661B2 (en) | 2018-03-02 | 2021-07-13 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for lowering triglycerides in a subject on concomitant statin therapy and having hsCRP levels of at least about 2 mg/L |
MA51766A (fr) | 2018-09-24 | 2020-12-16 | Amarin Pharmaceuticals Ie Ltd | Procédés de réduction du risque d'événements cardiovasculaires chez un sujet |
KR20240012390A (ko) | 2021-04-21 | 2024-01-29 | 애머린 파마슈티칼스 아일랜드 리미티드 | 심부전의 위험을 감소시키는 방법 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004014359A1 (fr) * | 2001-03-16 | 2004-02-19 | Thomas Jefferson University | Regulation d'apob permettant le traitement et le criblage de medicaments pour des troubles ou des syndromes cardiovasculaires et metaboliques |
EA014420B1 (ru) * | 2004-12-06 | 2010-12-30 | Релайэнт Фармасьютикалз, Инк. | Омега-3 жирные кислоты и дислипидемический агент для липидной терапии |
MX2008000915A (es) * | 2005-07-18 | 2008-04-04 | Reliant Pharmaceuticals Inc | Tratamiento con inhibidores de absorcion de colesterol basados en azetidinona y acidos grasos omega-3 y un producto de combinacion de los mismos. |
-
2007
- 2007-09-07 CN CNA2007800456489A patent/CN101553221A/zh active Pending
- 2007-09-07 EA EA200970359A patent/EA018734B1/ru not_active IP Right Cessation
- 2007-10-10 BR BRPI0719182-0A2A patent/BRPI0719182A2/pt not_active Application Discontinuation
- 2007-10-10 CN CNA2007800456667A patent/CN101553220A/zh active Pending
- 2007-10-10 KR KR1020097009523A patent/KR20090080070A/ko not_active Application Discontinuation
- 2007-10-10 AU AU2007307007A patent/AU2007307007A1/en not_active Abandoned
- 2007-10-10 EA EA200970360A patent/EA200970360A1/ru unknown
- 2007-10-10 JP JP2009532391A patent/JP2010505956A/ja active Pending
- 2007-10-10 CA CA002672919A patent/CA2672919A1/fr not_active Abandoned
- 2007-10-10 MX MX2009003921A patent/MX2009003921A/es unknown
- 2007-10-10 EP EP07852630A patent/EP2089014A4/fr not_active Withdrawn
- 2007-10-10 WO PCT/US2007/021631 patent/WO2008045465A1/fr active Application Filing
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2014034871A1 (fr) * | 2012-08-30 | 2014-03-06 | 株式会社 三和化学研究所 | Médicament pour la prévention ou le traitement de la dyslipidémie |
JPWO2014034871A1 (ja) * | 2012-08-30 | 2016-08-08 | 株式会社三和化学研究所 | 脂質異常症の予防又は治療薬 |
Also Published As
Publication number | Publication date |
---|---|
WO2008045465A1 (fr) | 2008-04-17 |
MX2009003921A (es) | 2009-08-31 |
KR20090080070A (ko) | 2009-07-23 |
EP2089014A1 (fr) | 2009-08-19 |
EA200970360A1 (ru) | 2009-10-30 |
CN101553221A (zh) | 2009-10-07 |
EA018734B1 (ru) | 2013-10-30 |
CN101553220A (zh) | 2009-10-07 |
BRPI0719182A2 (pt) | 2014-10-21 |
AU2007307007A1 (en) | 2008-04-17 |
CA2672919A1 (fr) | 2008-04-17 |
EP2089014A4 (fr) | 2009-12-09 |
EA200970359A1 (ru) | 2009-10-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2010505956A (ja) | Apo−bレベル低下のためのオメガ−3脂肪酸および脂質異常症剤 | |
JP5818403B2 (ja) | Apo−bレベルの減少のためのスタチンおよびオメガ−3脂肪酸 | |
US8871800B2 (en) | Statin and omega-3 fatty acids for reduction of Apo-B levels | |
CA2589654C (fr) | Acides gras omega-3 et agent dyslipidemique pour therapie lipidique | |
US20110092563A1 (en) | Statin and omega-3 fatty acids for lipid therapy | |
US20110251275A1 (en) | Omega-3 fatty acids for reduction of lp-pla2 levels | |
US20060211763A1 (en) | Treatment with Statin and Omega-3 Fatty Acids and a Combination Product Thereof | |
US20080306154A1 (en) | Treatment and prevention of major adverse cardiovascular events or major coronary evens by administering Omega-3 fatty acids | |
JP2008524120A (ja) | オメガ−3脂肪酸類及びpparアゴニスト及び/又はアンタゴニスト並びにその併用製品を用いた治療 |